• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The intracellular retention of newly synthesized platelet-activating factor.

作者信息

Lynch J M, Henson P M

出版信息

J Immunol. 1986 Oct 15;137(8):2653-61.

PMID:3093579
Abstract

The ether phospholipid platelet-activating factor (PAF) has been generally assumed to be released into the extracellular environment by the cells of origin, whereupon it effects its well-known mediator functions. However, during the generation of PAF by human neutrophils, it was noted that the majority of the measurable PAF remained associated with the cells. Accordingly, the intracellular and extracellular distribution of PAF was examined in neutrophils and several other cell types. No PAF was detected in association with unstimulated neutrophils. However, in stimulated neutrophils, PAF was produced and the majority of this material remained in association with the cells independent of the type of stimulus, dose of stimulus, or method of cell isolation used. This pattern of cell association of PAF was seen in all but one of the cell types tested. The retention of PAF by stimulated neutrophils was not due to spurious underestimates of the extracellular levels due to extracellular metabolism and inactivation of released PAF, nor to release followed by readsorption or binding of PAF to the cells. The retention of PAF also occurred in the presence of plasma and appears to be a common phenomenon. Thus, the majority of newly synthesized PAF appears to be retained within the cell and not released.

摘要

相似文献

1
The intracellular retention of newly synthesized platelet-activating factor.
J Immunol. 1986 Oct 15;137(8):2653-61.
2
The subcellular distribution of platelet-activating factor in stimulated human neutrophils.
J Immunol. 1990 Nov 1;145(9):3062-70.
3
Release of platelet-activating factor and the metabolism of leukotriene B4 by the human neutrophil when studied in a cell superfusion model.在细胞灌流模型中对人中性粒细胞释放血小板活化因子及白三烯B4代谢的研究。
J Immunol. 1989 Dec 1;143(11):3659-65.
4
Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes. Correlation of synthesis with release, functional events, and leukotriene B4 metabolism.受刺激的人多形核白细胞产生血小板活化因子。合成与释放、功能事件及白三烯B4代谢的相关性。
J Immunol. 1987 Jun 1;138(11):3918-26.
5
Release of newly synthesized platelet-activating factor (PAF) from human polymorphonuclear leukocytes under in vivo conditions. Contribution of PAF-releasing factor in serum.
J Immunol. 1992 Feb 1;148(3):872-80.
6
Synthesis and release of platelet-activating factor by stimulated human mononuclear phagocytes.
J Immunol. 1988 Mar 1;140(5):1618-24.
7
Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE.抗原引发用单克隆IgE致敏的小鼠骨髓来源肥大细胞释放血小板活化因子(PAF-乙醚)。
J Immunol. 1983 Dec;131(6):2958-64.
8
Endothelial cell associated platelet-activating factor (PAF), a costimulatory intermediate in TNF-alpha-induced H2O2 release by adherent neutrophil leukocytes.内皮细胞相关的血小板活化因子(PAF),是肿瘤坏死因子-α诱导黏附的中性粒细胞释放过氧化氢过程中的一种共刺激中间体。
J Immunol. 1995 Feb 1;154(3):1383-90.
9
Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes.血小板激活因子(Paf-乙酰醚)的生物合成。VII. 人白细胞中血小板激活因子的前体和乙酰转移酶活性
J Immunol. 1984 Aug;133(2):892-8.
10
Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during the stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils.过敏反应和吞噬作用中的血小板活化因子。I. 在离子载体A23187刺激和吞噬作用期间,人外周多形核白细胞和单核细胞释放血小板活化因子,但脱颗粒的嗜碱性粒细胞不释放。
Immunology. 1980 Aug;40(4):645-55.

引用本文的文献

1
Bioactive Ether Lipids: Primordial Modulators of Cellular Signaling.生物活性醚脂类:细胞信号传导的原始调节剂
Metabolites. 2021 Jan 8;11(1):41. doi: 10.3390/metabo11010041.
2
New insights into mechanisms of nuclear translocation of G-protein coupled receptors.G蛋白偶联受体核转位机制的新见解
Small GTPases. 2019 Jul;10(4):254-263. doi: 10.1080/21541248.2017.1282402. Epub 2017 Feb 10.
3
Nuclear localization of platelet-activating factor receptor controls retinal neovascularization.血小板活化因子受体的核定位控制视网膜新生血管形成。
Cell Discov. 2016 Jul 12;2:16017. doi: 10.1038/celldisc.2016.17. eCollection 2016.
4
Effects of acrolein on leukotriene biosynthesis in human neutrophils.丙烯醛对人中性粒细胞白三烯生物合成的影响。
Chem Res Toxicol. 2008 Dec;21(12):2424-32. doi: 10.1021/tx800333u.
5
Mobilization and margination of bone marrow Gr-1high monocytes during subclinical endotoxemia predisposes the lungs toward acute injury.亚临床内毒素血症期间骨髓Gr-1高表达单核细胞的动员和边缘化使肺部易发生急性损伤。
J Immunol. 2009 Jan 15;182(2):1155-66. doi: 10.4049/jimmunol.182.2.1155.
6
IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE).白细胞介素-10刺激活动期系统性红斑狼疮(SLE)患者单核细胞产生血小板活化因子。
Clin Exp Immunol. 2000 Dec;122(3):471-6. doi: 10.1046/j.1365-2249.2000.01392.x.
7
Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.用氯克罗孟(一种磷脂酶A2激活抑制剂)抑制受刺激的人多形核白细胞合成血小板活化因子。
Br J Pharmacol. 1996 Jul;118(6):1351-8. doi: 10.1111/j.1476-5381.1996.tb15544.x.
8
Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.细胞内血小板活化因子在革兰氏阳性菌感染性休克模型循环衰竭中的作用。
Br J Pharmacol. 1995 Dec;116(8):3191-8. doi: 10.1111/j.1476-5381.1995.tb15123.x.
9
Platelet-activating-factor-mediated pathogenesis in Lyme disease.血小板活化因子介导的莱姆病发病机制。
Infect Immun. 1996 Mar;64(3):1026-9. doi: 10.1128/iai.64.3.1026-1029.1996.
10
Oxidative stress in gastric mucosal injury: role of platelet-activating factor-activated granulocytes.
J Gastroenterol. 1995 Oct;30(5):565-71. doi: 10.1007/BF02367780.